Navigation Links
Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting

ctive anti-VEGF, VTA and VEA technologies. These positive developments in our clinical and preclinical programs reinforce our belief that the future for Peregrine has never been brighter, and we look forward to progressing these programs both on our own and with partners and collaborators going forward."

Highlights of seven of Peregrine's AACR presentations this week follow.

Peregrine's Selective Anti-VEGF Antibody Program

Drugs blocking vascular endothelial growth factor (VEGF) are proving very successful as anti-cancer agents, and for the first time researchers presented animal data on Peregrine's anti-VEGF antibodies that selectively block binding to the second of the two VEGF receptors. Current anti-VEGF drugs such as Avastin(R) block binding to both receptors, yet in preclinical studies comparing Peregrine's selective anti-VEGF antibody to Avastin, the selective antibodies compared favorably on all efficacy parameters assessed, inhibiting tumor growth by 90% in preclinical cancer models. Antibodies with greater selectivity may have advantages in clinical use since they have the potential to only inhibit angiogenesis while not impairing other functions of VEGF. Additional data that was presented showing the efficacy of Peregrine's fully human selective anti-VEGF antibody (R3) is expected to help facilitate the progress of this program towards clinical trials.

Broad Applicability and Versatility of Bavituximab, Peregrine's Targeted Anti-PS Antibody

Researchers affiliated with Peregrine presented a number of preclinical studies demonstrating the versatility and broad anti-cancer utility of bavituximab in major cancer models. They also reported data validating bavituximab's unique mechanism of action and supporting potential new applications of Peregrine's anti-PS technology platform. These included:

    *  Data supporting the potential use of bavituximab to enhance immune

       responses to existing tumors and as a po
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/30/2014)... 30, 2014   NxStage® Kidney Care, Inc ., a ... is proud to host the grand opening ceremony of its ... W. 16 th Street on November 20, 2014 from ... trained medical staff who are committed to providing patients with ... benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... Oct. 30, 2014 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... release third quarter 2014 financial results on Wednesday, November ... The Company,s management will hold a conference call at ... which is 8:30 p.m., Beijing Time on November 6, ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2
... Reportlinker.com announces that a new market research ... European Markets for Dental Bone Graft Substitutes, ... http://www.reportlinker.com/p0339837/European-Markets-for-Dental-Bone-Graft-Substitutes-Dental-Membranes-and-Tissue-Engineering-2011.html In ... graft substitutes and other biomaterials grew by 4.4% ...
... (Nasdaq: VRNM ), a pioneer in the ... today announced key 2010 accomplishments and 2011 Company ... a significant year of transition for Verenium as we ... building the next leading industrial enzymes company," said Carlos ...
Cached Medicine Technology:Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 2Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 3Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 4Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 5Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 6Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 7Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 8Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 9Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 10Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 11Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 12Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 13Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 14Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 15Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 16Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 17Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 18Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 19Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 20Verenium Announces 2010 Business Update and Outlook for 2011 2Verenium Announces 2010 Business Update and Outlook for 2011 3Verenium Announces 2010 Business Update and Outlook for 2011 4Verenium Announces 2010 Business Update and Outlook for 2011 5
(Date:10/30/2014)... Five months after their expansion, the AV ... branding and a website to accompany their recent change ... promotion to name partner earlier this year, Hodgkinson Street ... name and better reflect their combined litigation expertise. As ... to implement new branding reflects Hodgkinson Street Mepham’s collaborative ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... California (PRWEB) October 30, 2014 REV'D ... bars are now available through a unique service called, ... site designed to empower the everyday athlete. The Feed ... best athletes and created a system to pass that ... to see REV’D® is now available on The Feed!” ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3
... dysfunctions- painful intercourse, sexual dissatisfaction and a multitude ... the patients and their doctors communicated better, most ... all women, as they go through menopause, will ... known as genital atrophy. ,This results in ...
... back with a vengeance. The killer disease of the past is ... partner in its destructive mission. Full-blown cases of AIDS coupled with ... in Africa alone. What is alarming is that the death rate ... no signs of the destruction slowing down. ,Health experts argue ...
... deaths due to asthma can be prevented if the ... disease. According to WHO, around 150 million people suffer ... due to the disease every year. Asthma is a ... characterized by sudden recurring attacks of labored breathing, chest ...
... that wound healing in depressed people is four times slower ... a place in the latest issue of the journal, “Psychosomatic ... on the rate of wound healing, according to the researchers. ... the immune system, which may keep a wound from healing ...
... injure the donor, it is now established without doubt that a ... person needing it. And the good news is that the donor ... his/her liver. ,Donation of a piece of the liver's right ... It is increasingly being performed in the West where the demand ...
... for the treatment of cancer has nearly,doubled during ... survey of pharmaceutical,companies.,Currently, 170 pharmaceutical and biotechnology firms ... treatment of various,cancers, up from 215 in 1995. ... and chemotherapy. For lung cancer, the leading cause ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: